Price
CHART BY
Frequently asked questions
What is Voyager's market capitalization?
The market capitalization of Voyager is $208.27M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Voyager?
Voyager's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.813. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Voyager's stock?
Currently, 11 analysts cover Voyager's stock, with a consensus target price of $14.89. Analyst ratings provide insights into the stock's expected performance.
What is Voyager's revenue over the trailing twelve months?
Over the trailing twelve months, Voyager reported a revenue of $34.46M.
What is the EBITDA for Voyager?
Voyager's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$113.37M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Voyager?
Voyager has a free cash flow of -$121.42M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Voyager have, and what sector and industry does it belong to?
Voyager employs approximately 141 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Voyager's shares?
The free float of Voyager is 51.39M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $208.27M
- EPS (TTM)
- -$1.813
- Free Float
- 51.39M
- Revenue (TTM)
- $34.46M
- EBITDA (TTM)
- -$113.37M
- Free Cashflow (TTM)
- -$121.42M
Pricing
- 1D span
- $3.339$3.496
- 52W span
- $2.935$5.55
Analyst Ratings
The price target is $14.89 and the stock is covered by 11 analysts.
Buy
11
Hold
0
Sell
0
Information
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.
- Employees
- 141
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- VYGR
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet